Signatera now has >85 peer-reviewed publications with clinical validation across multiple cancer types and indications AUSTIN, Texas, September 16, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), ...
Source LinkSignatera now has >85 peer-reviewed publications with clinical validation across multiple cancer types and indications AUSTIN, Texas, September 16, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), ...
Source Link
Comments